ASCL1 and central nervous system cancer: At 14 dpi, when a majority of glioma cells had been reprogrammed into neurons by ASCL1 (Figure 4), immunocytochemical analysis showed that 81.4% of glioma cells were positive for Ki67 in the control group, whereas only 23.1% of them were Ki67-positive in the ASCL1 group (Figure 7A,B).